• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TICLOPIDINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TICLOPIDINE chembl:CHEMBL833 Approved

    Alternate Names:

    TICLOPIDINE
    4-C-32
    TICLID®
    53-32C
    TICLOPIDINUM
    TICLOPIDINA
    chembl:CHEMBL833
    pubchem.compound:5472
    chemidplus:55142-85-3
    rxcui:10594
    drugbank:00208

    Drug Info:

    FDA Approval 1991
    Drug Class small molecule
    Drug Indications Platelet Aggregation Inhibitors
    Drug Class platelet aggregation inhibitors
    Year of Approval 1991
    (2 More Sources)

    Publications:

    Hirata K et al., 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study., Pharmacogenomics J
    Storey, 2001, The P2Y12 receptor as a therapeutic target in cardiovascular disease., Platelets
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Gachet, 2005, The platelet P2 receptors as molecular targets for old and new antiplatelet drugs., Pharmacol. Ther.
    Zhan et al., 2007, Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists., J. Mol. Graph. Model.
    Boeynaems et al., 2005, P2Y receptor antagonists in thrombosis., Curr Opin Investig Drugs
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
  • TICLOPIDINE   P2RY12

    Interaction Score: 3.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11454254 11752352 15955565 17110146 15816504 20938371


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • TICLOPIDINE   HLA-C

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • TICLOPIDINE   PTAFR

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TICLOPIDINE   HLA-DQB1

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • TICLOPIDINE   HLA-A

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • TICLOPIDINE   HLA-B

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • TICLOPIDINE   HLA-DRB1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • TICLOPIDINE   CYP2B6

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17638512


    Sources:
    PharmGKB

  • TICLOPIDINE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TICLOPIDINE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TICLOPIDINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TICLOPIDINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TICLOPIDINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: TICLOPIDINE

    • Version: 01-August-2011

    Alternate Names:
    TICLOPIDINE Primary Drug Name

    Drug Info:
    Year of Approval 1991
    Drug Class platelet aggregation inhibitors

    Publications:

  • TdgClinicalTrial: TICLOPIDINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Platelet Aggregation Inhibitors
    Drug Class small molecule
    FDA Approval 1991

    Publications:

  • DTC: TICLOPIDINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL833 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: ticlopidine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hirata K et al., 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study., Pharmacogenomics J
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Gachet, 2005, The platelet P2 receptors as molecular targets for old and new antiplatelet drugs., Pharmacol. Ther.

  • TTD: Ticlopidine

    • Version: 2020.06.01

    Alternate Names:
    D05LBU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL833

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21